Azienda di Servizi alla Persona
Pavia, 27100, Italy
NCT Number: NCT04932070
Polycystic Ovary Syndrome (PCOS) is the most frequent endocrine disease in female reproductive-age. Recently, increasing evidence has shown that natural plant-based products may play a role in PCOS management. Previous study in PCOS preclinical model and in humans demonstrated that berberine is an effective insulin sensitizer and improves homeostasis of metabolic, inflammatory and hormonal disorders. However, to date there is no clinical study that considers globally all the activities carried out by berberine in PCOS clinical features. Given this background, aim of this study was to evaluate in normal-overweight PCOS women with normal menses the berberine effectiveness on: insulin resistance by Homeostasis Model Assessment (HOMA); inflammation by C-Reactive Protein (CRP), TNF-alpha; lipid metabolism; sex hormone profile and symptoms correlated to hyperandrogenism, such as acne, by Global Acne Grading System (GAGS) and Cardiff Acne Disability Index (CADI); body composition by dual-energy X-ray absorptiometry. All these parameters were collected at baseline and 60 days after supplementation with a new bioavailable and safe berberine formulation. Finally, adverse effects were assessed by liver and kidney functions. To evaluate statistically significant pre- post-supplementation changes, fitted a linear mixed model for each investigated endpoint was performed.
Looking for future studies?
Notify Me20 year–35 year
Female
Interventional
Not applicable
Pavia, 27100, Italy
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
2 daily oral doses (one before lunch and one dinner) of 550 mg of berberine tablets
Time frame: Changes from baseline insulin resistance at 8 weeks
Homeostasis Model Assessment (pt), for evaluate insulin resistance if > 2.4
Time frame: Changes from baseline inflammation at 8 weeks
C-Reactive Protein (mg/dl)
Time frame: Changes from baseline inflammation at 8 weeks
Tumor Necrosis Factor alpha (pg/ml)
Time frame: Changes from baseline lipid profile at 8 weeks
Total Cholesterol (mg/dl), High Density Lipoprotein Cholesterol (mg/dl), Low Density Lipoprotein Cholesterol (mg/dl), Very Low Density Lipoprotein (mg/dl),Triglycerides (mg/dl)
Time frame: Changes from baseline Carbohydrate profile at 8 weeks
Glycemia (mg/dl)
Time frame: Changes from baseline Carbohydrate profile at 8 weeks
Insulin (mcU/ml)
Time frame: Changes from baseline Hormonal profile at 8 weeks
Sex Hormone Binding Globulin (nmol/l)
Time frame: Changes from baseline Hormonal profile at 8 weeks
Testosterone (ng/ml)
Time frame: Changes from baseline Hormonal profile at 8 weeks
Free Androgen Index (ratio)
Time frame: Changes from baseline safety at 8 weeks
Aspartate aminotransferase (IU/l), alanine aminotransferase (IU/l)
Time frame: Changes from baseline safety at 8 weeks
Total bilirubin (mg/dl)
Time frame: Changes from baseline safety at 8 weeks
Gamma Glutamyl Transferase (U/I), Creatine Phosphokinase (U/I)
Time frame: Changes from baseline anthropometry at 8 weeks
waist circumference (cm), hip circumference (cm)
Time frame: Changes from baseline anthropometry at 8 weeks
Weight (kg)
Time frame: Changes from baseline anthropometry at 8 weeks
Body Mass Index (Kg/m2)
Time frame: Changes from baseline body composition at 8 weeks
Fat mass (g), lean mass (g), visceral adipose tissue (g)
Time frame: Changes from baseline acne assessment at 8 weeks
Global Acne Grading System (scale): each type of acne lesion is given a value depending on severity: no lesions = 0, comedones = 1, papules = 2, pustules = 3, and nodules = 4. Each of the location was graded separately on 0-4 scale, with the most severe lesion within that location determining the local score. The severity was then graded according to the global score which is the summation of all local scores. A score of 1-6 was considered mild; 7-18, moderate; 19- 26, severe; and 27-32, very severe. The maximum score was 32
Time frame: Changes from baseline acne assessment at 8 weeks
Cardiff Acne Disability Index (scale): the Cardiff Acne Disability Index consists of five questions with a Likert scale, four response categories (0-3). The five questions relate to feeling of aggression, frustration, interference with social life, avoidance of public changing facilities and appearance of the skin-all over the last month-and an indication of how bad the acne was now. The CADI score was calculated by summing the score of each question resulting in a possible maximum of 15 and minimum of 0. CADI scores were graded as low (0-4), medium (5-9), and high (10-15)
Azienda di Servizi alla Persona di Pavia
Other
Berberine is an Effective Insulin Sensitizer and Improves Homeostasis of Metabolic and Hormonal Disorders in Women With Polycystic Ovary Syndrome: a Novel Treatment Strategy for PCOS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07585396
Adnexal Diseases, Cysts
Cairo, Egypt
View Trial DetailsNCT07635082
Adnexal Diseases, Cysts
Kafr ash Shaykh, Kafr el-Sheikh Governorate, Egypt
View Trial DetailsNCT04120597
Adnexal Diseases, Cysts
Nanchang, Jiangxi, China
View Trial DetailsNCT07604870
Adnexal Diseases, Body Weight
Elâzığ, Turkey (Türkiye)
View Trial Details